Volume | 597,144 |
|
|||||
News | - | ||||||
Day High | 21.87 | Low High |
|||||
Day Low | 20.41 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Stevanato Group SpA | STVN | NYSE | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
21.42 | 20.41 | 21.87 | 21.34 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
3,718 | 597,144 | $ 20.72 | $ 12,371,655 | - | 20.01 - 36.30 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
14:13:19 | 200 | $ 20.72 | USD |
Stevanato Group SpA Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
6.06B | 295.54M | - | 1B | 142.85M | 0.48 | 42.46 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Stevanato News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical STVN Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 27.60 | 27.88 | 20.01 | 21.81 | 1,901,638 | -6.88 | -24.93% |
1 Month | 29.00 | 29.675 | 20.01 | 23.92 | 757,497 | -8.28 | -28.55% |
3 Months | 30.45 | 34.00 | 20.01 | 27.35 | 531,354 | -9.73 | -31.95% |
6 Months | 29.71 | 34.73 | 20.01 | 27.84 | 386,517 | -8.99 | -30.26% |
1 Year | 27.62 | 36.30 | 20.01 | 28.97 | 361,422 | -6.90 | -24.98% |
3 Years | 16.65 | 36.30 | 13.355 | 23.12 | 371,067 | 4.07 | 24.44% |
5 Years | 16.65 | 36.30 | 13.355 | 23.12 | 371,067 | 4.07 | 24.44% |
Stevanato Description
Italy-based Stevanato Group is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. Stevanato's revenue is geographically diversified, with 60% of sales from Europe, the Middle East and Africa (EMEA), 27% in North America, 10% in Asia-Pacific (APAC), and 3% in South America. |